88 results about "Vaginal dryness" patented technology

Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and / or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The present invention is directed to novel heterocyclic benzo[c]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

The invention relates to the technical field of medical gels, and in particular relates to a recombinant human collagen gel and a preparation method thereof. The recombinant human collagen gel consists of the following raw materials in percentage by weight: 1-3% of small-molecule collagen, 1.5-2.5% of glycerol, 1-2% of chitosan quaternary ammonium salt, 0.5-1.5% of sodium hyaluronate, 0.5-1.5% of epsilon-polylysine, 0.3-0.7% of borneol, 0.3-0.7% of poloxamer, 0.3-0.7% of coenzyme Q10, 0.3-0.7% of butanediol and the balance of purified water. The recombinant human collagen gel provided by the invention has effects of moisture retention and isolation, can improve vaginal atrophy, increase vaginal elasticity and relieve dyspareunia, and also can improve the wettability and the dry state of a vagina, relieve dry and coarse stabbing pain symptoms of cunnus, and ease itching, calor, skin mucous membrane fissure and diffuse superficial bleeding caused by vaginal dryness.

The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition.

The invention relates to the technical field of antibacterial gel, in particular to chitosan antibacterial gel and a preparation method thereof. Each liter of the chitosan antibacterial gel comprises the following raw materials by weight: 5-30g of modified chitosan, 2.5-10g of carbomer, 1-1.8g of alum, 2-40g of glycerol, 0.3-10g of lactic acid, 0.1-0.8g of menthol and 2-8g of sodium carboxymethylcellulose. The chitosan antibacterial gel which is good in curative effect, can be used for preventing relapse of inflammation and is harmless to human body is prepared by using the synergistic effect of modified chitosan serving as a major raw material as well as carbomer, alum, glycerol, lactic acid and sodium carboxymethylcellulose serving as auxiliary materials, and is suitable for preventing, treating and nursing various vaginal bacterial infections, trichomonas infections, mixed infections, vulvitis, leucorrhea, candidal infection as well as wound infections of cervix uteri, genital tract and mucous membrane. By using the chitosan antibacterial gel, wound healing after physical treatment of cervical erosion is promoted, and nursing of vaginal dryness as well as cross infections in sexual intercourse and the like is improved.

The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

The invention relates to an ordinary treatment medicine for vagina dryness, and in particular relates to recombinant human-derived collagen vagina gel for vaginal dryness. The recombinant human-derived collagen vagina gel comprises the following components in percentage by mass: 0.05-1% of recombinant human-derived collagen, 10-30% of poloxamer 407, 0.5-6% of poloxamer 188, 0.1-2% of sodium hyaluronate, 1-4% of glycerinum, an antibacterial preservative which comprises 0.1-1% of phenoxyethanol, 0.05-3% of sodium methylparaben, 0.01-2% of propylparaben, and the balance of water. By adopting the recombinant human-derived collagen vagina gel, the vagina elasticity can be improved, vaginal atrophy can be alleviated, dyspareunia can be relieved, and the sex satisfaction can be improved; by increasing secreta, improving the vagina wetness and alleviating the dryness of vaginas, pruritus, hotness and chapped skin caused by dryness can be remedied, and the symptoms of dryness and stabbing pain of vulvovagina can be alleviated. In addition, the product cannot affect the pH value of vaginas when used in the vaginas, is free of adverse reaction, and is worthy of clinical popularization and application.

The invention relates to a water-based human body lubricating liquid containing a compound antibacterial agent, which adopts water-soluble chlorhexidine, nano-silver complex antibacterial liquid, Cnidium chinensis extract, propolis extract, honeysuckle extract, and aloe extract , purslane extract, glycerol, propylene glycol, preservatives, macromolecular mucopolysaccharide, carbomer, 2-sodium acrylate homopolymer, hydroxyl ethyl cellulose, pH regulator and sterilized deionized water made. The water-based human body lubricant not only has the functions of lubricating, nourishing and caring, but also is mild in nature, has no adverse reaction to the human body, is healthy and environmentally friendly, and is easy to clean afterwards, not greasy, and has good anti-inflammatory and antibacterial functions, and its antibacterial function does not affect Beneficial bacteria. This water-based body lubricant can be used in couples during sex to help with vaginal dryness or over condoms.

The invention relates to the technical field of preparation of colpitis medicines, and especially relates to a vaginal gel and a preparation method thereof in order to solve the technical problem of unsatisfactory bacteriostasis, lubrication and moisture retention effects of existing vaginal gel products. The vaginal gel mainly comprises sodium hyaluronate, vitamin E succinate modified hyaluronic acid, EGF (epidermal growth factors), vitamins C, calcium chloride, pentanediol, glycerin, Rhodicare and a buffer system adopting disodium hydrogen phosphate-citric acid as gel. The vaginal gel has anti-inflammatory activity, improves the wetness of vaginas, is used for treating vaginal inflammatory diseases and alleviating vaginal dryness or used as a human body lubricant, has a vaginal mucosa squamous cell layer restoration promoting effect, can improve vaginal mucosa layer thinning and restore small injuries in vaginas to recover the elasticity and the softness of the vaginal mucosa, and is suitable for colpitis and vagina dryness people.

The present invention relates to topical vaginal compositions in gel form containing immune mediators, growth factors, chemotactic factors and antibacterial / antiviral factors extracted from bovine colostrum, and optionally other ingredients with complementary activity.

Compositions in gel form or suppository are provided for treatment of vaginal dryness, wherein the composition comprises certain herbal compounds, with or without a vitamin such as, for example, vitamin A, C, D or E. The compositions may include an anti-bacterial agent and are applied to the affected area in an amount which is effective to provide the required relief when applied over a period of time.

The invention relates to a commonly used drug spermicide for contraception, in particular to biodegradable contraception gel with antibacterial effect, and belongs to an autonomous external contraceptive. On the basis of the biodegradable contraception gel, exact quantitative administration can be realized by virtue of a disposable long cylinder applicator. The antibacterial contraception gel is composed of a spermicide, biodegradable gel and water. The gel is specifically vaginal gel compounded by silk fibroin and chitosan and comprises the following components in mass concentration: 2-8% ofsilk fibroin, 0.5-2% of chitosan, 0.5-2% of carbomer 940 or hydroxypropyl methyl cellulose, 5-12% of glycerol and propylene glycol and the balance of water, and pH value is regulated to be 3.5-5. Theproduct can achieve the effects of rapidly killing sperms and carrying out contraception and birth control, also has antibacterial effect and can prevent and alleviate germ infection in genital tract.Ingredients of the gel are biodegradable, and degradation products can be absorbed and have the effect of alleviating vaginal dryness and atrophy to some extent. The gel preparation fills a needle tube type tool and can be directly injected deep inside a vagina, and the aim of the exact quantitative administration is achieved. The product has good biocompatibility, can not influence pH of the vagina, has no side effect and is worthy of being popularized and applied in clinic.

The subject of the invention is compositions for vaginal use containing lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and / or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the changes in the physiological trophism of the vulvar and vaginal tissue and mucosa.

Novel methods for reduction or elimination the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes type 2, loss of muscle mass, adiposity, Alzheimer's disease, loss of cognition, loss of memory, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and an antiestrogen or a selective estrogen receptor modulator, particularly compounds having the general structure:Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

The invention discloses a medicinal composition for treating vaginal dryness. The composition comprises 50-80 wt% of Oviductus Ranae, and 20-50 wt% of Chinese herbal powder. The medicinal composition has effects in invigorating kidney and vital essence, nourishing Yin and blood, promoting qi circulation to remove stagnation; and can be used for treating symptoms such as vaginal dryness, sexual pain and sexual hypoactivity due to perimenopause or ovary dysfunction. The composition is simple in formula and production, and effective in curative effect, is prepared from pure Chinese medicinal materials, and has no toxic and side effects.

Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and / or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to the subject suffering from the disorders are provided. In addition, intra-vaginal administration of cholinergic agonists such as muscarinic receptor agonists to patients suffering from interstitial cystitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness is also provided.

The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

The invention discloses a functional water-soluble lubricant containing hyaluronic acid. The lubricant comprises the following components of, in percentage by mass, 20% of compound polyols, 0.5% of the hyaluronic acid, 0.1% of carbomer, 10% of a compatibility promoting aid, 10% of a plant extract and plant essential oil and the balance water; and the pH value of the water-soluble lubricant is controlled to be maintained at 3.8-5.5 through a pH value regulator. The lubricant is mainly used for people suffering from gradual vaginal dryness, has the effects of lubricating, reducing dryness and reducing a pain caused by friction during sexual intercourse; the lubricant is a water-soluble lubricant, and is easy to metabolize and absorb, convenient to clear and free of greasy feeling; and the lubricant has good compatibility with naturally secreted body fluid of a human body, is consistent with the pH value of a normal physiological environment of a female vagina, and does not destroy a micro-ecological environment of a female private part.

The invention discloses a gel dressing for preventing and inhibiting HPV virus infection. The gel dressing is prepared from hydrogel and traditional Chinese medicine extracts uniformly dispersed in the hydrogel, wherein the traditional Chinese medicine extracts include radix sophorae flavescentis extract, scouring rush extract, brucea javanica extract, fructus cnidii extract, anthocyanin, carrageenan, natural equilibrium factors and borneol; and the hydrogel includes carboxymethyl cellulose sodium, ethylparaben, propylene glycol, mannitol, antibacterial peptide, glycerol, a water-based powdered lubricant, diethanol amine and distilled water. By adopting the technical scheme, the gel dressing has effects of moistening the skin, protecting the heart, conditioning the premenstrual syndrome and the like by adding anthocyanin; and the gel dressing can effectively improve human immunity, moisten genital tracts, protect mucous membranes and effectively relieve vaginal dryness and other symptoms by adding carrageenan.

The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and / or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.

The invention relates to Zhuyan medicinal liquor which has the effects of enriching yin, nourishing kidney, strengthening yang, adjusting internal secretion, nourishing gonad and ovary, tranquilizing mind by nourishing heart, tonifying brain, warming kidney, strengthening tendons and bones, relaxing bowels, enhancing immunity of organism and the like and aims at overcoming the defects that the existing medicinal liquor does not have the efficacies of tranquilizing mind by nourishing heart, tonifying brain, delaying climacteric, relaxing bowels and the like. The Zhuyan medicinal liquor has multiple efficacies and a good treatment effect and can be used for treating insomnia and dreamful sleep, habitual constipation, sexual apathy and vaginal dryness during intercourse, delaying the climacteric, recovering the sexual function to realize intercourse after being taken by old people, enhancing memory, preventing encephalatrophy and senile plaque, improving immunity and auxiliarily treating the cervical or lumbar diseases. According to the technical scheme, 100jin Zhuyan medicinal liquor contains the following components and contents: 200-300g of fructus cnidii, 200-300g of schisandra chinensis, 200-300g of cistanche, 200-300g of ginseng, 200-300g of radix polygonum multiflorum preparata, 200-300g of white poria, 200-300g of rehmannia root, 200-300g of asparagus fern, 100-150g of radix morindae officinalis, 100-150g of ligusticum wallichii, 100-150g of dendrobe, 100-150g of Chinese yam, 100-150g of prepared liquorice root, 100-150g of spina date seed, 150-200g of teasel root, 150-200g of loranthus parasiticus, 150-200g of longan aril and 150-200g of eucommia ulmoides; and all the components are soaked for three months to obtain the Zhuyan medicinal liquor, and the Zhuyan medicinal liquor is used after slag removal.

The present invention relates to the use of keratinocyte growth factor (KGF / FGF7) and pharmaceutical compositions thereof in the treatment of vaginal atrophy, dysuria, vaginal pain and / or vaginal dryness induced by a post-menopausal state, by surgical intervention, by illness and / or by chemotherapy or radiotherapy treatments.

The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2, and / or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable purinergic receptor agonists include nucleotide triphosphates such as uridine 5-triphosphate, cytidine 5'-triphosphate and adenosine 5'-triphosphate; dinucleotide polyphosphates such as P<1>, P<4>-di(uridine-5') tetraphosphate; and their analogs. These purinergic receptor agonists are useful in stimulating cervical and vaginal secretions and treating vaginal dryness in mammals.